The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus

被引:0
|
作者
Parlar, Mehmet Akif [1 ]
Mutlu, Hakan [1 ]
Dogantekin, Betul [1 ]
Musaoglu, Ismail Serhat [1 ]
Albayrakoglu, Nisa Demirbosnak [1 ]
Yavuz, Mustafa Lutfi [2 ]
Ozbolat, Zehra Busra [3 ]
Kaplan, Mustafa [1 ]
机构
[1] Univ Hlth Sci, Sultan Abdulhamid Han Training & Res Hosp 2, Dept Internal Med, Tibbiye St, TR-34668 Istanbul, Turkiye
[2] Istanbul Univ, Fac Med, Dept Cardiol, TR-34093 Istanbul, Turkiye
[3] Cerkezkoy State Hosp, Dept Chest Dis, Tekirdag Prov Hlth Directorate, TR-59100 Tekirdag, Turkiye
关键词
diabetes mellitus; fatty pancreas; fatty liver; statin; steatosis; ADIPOSE-TISSUE INFLAMMATION; INSULIN-SECRETION; GLUCOLIPOTOXICITY; CHOLESTEROL; DYSFUNCTION; DISEASE; ATORVASTATIN; SIMVASTATIN; STEATOSIS; EFFICACY;
D O I
10.3390/diagnostics15040426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic beta-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. Methods: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. Results: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, p = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, p = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, p = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (beta +/- SE = -0.16 +/- 0.05, p = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (beta +/- SE = -0.16 +/- 0.07, p = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (beta +/- SE = 0.17 +/- 0.06, p = 0.011) and pitavastatin (beta +/- SE = 0.19 +/- 0.07, p = 0.008) were independently associated with an increase in log(PFF). Conclusions: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Association of statin use and development of renal dysfunction in type 2 diabetes-The Hong Kong Diabetes Registry
    Luk, Andrea O.
    Yang, Xilin
    Ma, Ronald C.
    Ng, Vanessa W.
    Yu, Linda W.
    Lau, Winnie W.
    Ozaki, Risa
    Chow, Francis C.
    Kong, Alice P.
    Tong, Peter C.
    Chan, Juliana C.
    So, Wingyee
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 88 (03) : 227 - 233
  • [32] Impact of Diabetes Mellitus on Coronary Atherosclerosis and Plaque Composition Under Statin Therapy - Subanalysis of the TRUTH Study
    Nozue, Tsuyoshi
    Yamamoto, Shingo
    Tohyama, Shinichi
    Fukui, Kazuki
    Umezawa, Shigeo
    Onishi, Yuko
    Kunishima, Tomoyuki
    Sato, Akira
    Nozato, Toshihiro
    Miyake, Shogo
    Takeyama, Youichi
    Morino, Yoshihiro
    Yamauchi, Takao
    Muramatsu, Toshiya
    Hibi, Kiyoshi
    Terashima, Mitsuyasu
    Michishita, Ichiro
    CIRCULATION JOURNAL, 2012, 76 (09) : 2188 - 2196
  • [33] Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution
    Bozzetto, Lutgarda
    Prinster, Anna
    Mancini, Marcello
    Giacco, Rosalba
    De Natale, Claudia
    Salvatore, Marco
    Riccardi, Gabriele
    Rivellese, Angela A.
    Annuzzi, Giovanni
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 (01) : 39 - 44
  • [34] Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects
    Valle, Adamo
    Catalan, Victoria
    Rodriguez, Amaia
    Rotellar, Fernando
    Valenti, Victor
    Silva, Camilo
    Salvador, Javier
    Fruehbeck, Gma
    Gomez-Ambrosi, Javier
    Roca, Pilar
    Oliver, Jordi
    LIVER INTERNATIONAL, 2012, 32 (06) : 951 - 961
  • [35] Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
    Li, Tian
    Providencia, Rui
    Mu, Nan
    Yin, Yue
    Chen, Mai
    Wang, Yishi
    Liu, Manling
    Yu, Lu
    Gu, Chunhu
    Ma, Heng
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [36] GCKR polymorphism influences liver fat content in patients with type 2 diabetes
    Petit, Jean-Michel
    Masson, David
    Guiu, Boris
    Rollot, Fabien
    Duvillard, Laurence
    Bouillet, Benjamin
    Brindisi, Marie-Claude
    Buffier, Perrine
    Hillon, Patrick
    Cercueil, Jean-Pierre
    Verges, Bruno
    ACTA DIABETOLOGICA, 2016, 53 (02) : 237 - 242
  • [37] Visceral fat thickness predicts fatty liver in Koreans with type 2 diabetes mellitus
    Kim, Hai Jin
    Cho, Min Ho
    Park, Jong Suk
    Nam, Ji Sun
    Kang, Eun Seok
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Eun Jig
    Lim, Sung Kil
    Kim, Kyung Rae
    Lee, Hyun Chul
    Huh, Kap Bum
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2008, 23 (02) : 256 - 261
  • [38] Antihypertensive therapy in diabetes mellitus - Guidelines of the Austrian Diabetes Association 2016
    Schernthaner, Guntram
    Drexel, Heinz
    Rosenkranz, Alexander
    Schernthaner, Gerit-Holger
    Watschinger, Bruno
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S62 - S67
  • [39] Association Between Elevated Thyroid Peroxidase Antibody and Abdominal Fat Distribution in Patients with Type 2 Diabetes Mellitus
    Hu, Ye
    Zheng, Jia
    Ye, Xiao
    Song, Yingxiang
    Wu, Xiaohong
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 863 - 871
  • [40] Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
    Batrak, G. A.
    Myasoedova, S. E.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2010, 9 (03): : 68 - 72